These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10928951)

  • 1. Disparate ligand-mediated Ca(2+) responses by wild-type, mutant Ser(200)Ala and Ser(204)Ala alpha(2A)-adrenoceptor: G(alpha15) fusion proteins: evidence for multiple ligand-activation binding sites.
    Pauwels PJ; Colpaert FC
    Br J Pharmacol; 2000 Aug; 130(7):1505-12. PubMed ID: 10928951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneous ligand-mediated Ca(++) responses at wt and mutant alpha(2A)-adrenoceptors suggest multiple ligand activation binding sites at the alpha(2A)-adrenoceptor.
    Pauwels PJ; Colpaert FC
    Neuropharmacology; 2000 Aug; 39(11):2101-11. PubMed ID: 10963753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of ligand activation of alpha 2-adrenoceptor subtypes under conditions of equal G alpha protein stoichiometry.
    Pauwels PJ; Wurch T; Tardif S; Finana F; Colpaert FC
    Naunyn Schmiedebergs Arch Pharmacol; 2001 May; 363(5):526-36. PubMed ID: 11383713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial to complete antagonism by putative antagonists at the wild-type alpha(2C)-adrenoceptor based on kinetic analyses of agonist:antagonist interactions.
    Pauwels PJ; Colpaert FC
    Br J Pharmacol; 2000 Dec; 131(7):1385-90. PubMed ID: 11090111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced stability of wild-type and constitutively active alpha(2A)-adrenoceptors by ligands with agonist, silent and inverse agonist properties.
    Pauwels PJ; Tardif S
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):134-41. PubMed ID: 12122500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facilitation of constitutive alpha(2A)-adrenoceptor activity by both single amino acid mutation (Thr(373)Lys) and g(alphao) protein coexpression: evidence for inverse agonism.
    Pauwels PJ; Tardif S; Wurch T; Colpaert FC
    J Pharmacol Exp Ther; 2000 Feb; 292(2):654-63. PubMed ID: 10640303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins.
    Pauwels PJ; Tardif S; Colpaert FC; Wurch T
    Biochem Pharmacol; 2001 May; 61(9):1079-92. PubMed ID: 11301041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand-receptor interactions as controlled by wild-type and mutant Thr(370)Lys alpha2B-adrenoceptor-Galpha15 fusion proteins.
    Pauwels PJ; Tardif S; Finana F; Wurch T; Colpaert FC
    J Neurochem; 2000 Jan; 74(1):375-84. PubMed ID: 10617142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissimilar pharmacological responses by a new series of imidazoline derivatives at precoupled and ligand-activated alpha 2A-adrenoceptor states: evidence for effector pathway-dependent differential antagonism.
    Pauwels PJ; Rauly I; Wurch T
    J Pharmacol Exp Ther; 2003 Jun; 305(3):1015-23. PubMed ID: 12649300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agonist efficacy at the alpha2A-adrenoceptor:G alpha15 fusion protein: an analysis based on Ca2+ responses.
    Pauwels PJ; Finana F; Tardif S; Colpaert FC; Wurch T
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Jun; 361(6):672-9. PubMed ID: 10882043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G-protein activation by putative antagonists at mutant Thr373Lys alpha2A adrenergic receptors.
    Wurch T; Colpaert FC; Pauwels PJ
    Br J Pharmacol; 1999 Feb; 126(4):939-48. PubMed ID: 10193774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for protean agonism of RX 831003 at alpha 2A-adrenoceptors by co-expression with different G alpha protein subunits.
    Pauwels PJ; Rauly I; Wurch T; Colpaert FC
    Neuropharmacology; 2002 May; 42(6):855-63. PubMed ID: 12015212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors.
    Newman-Tancredi A; Nicolas JP; Audinot V; Gavaudan S; Verrièle L; Touzard M; Chaput C; Richard N; Millan MJ
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):197-206. PubMed ID: 9750005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Agonist-directed trafficking of porcine alpha(2A)-adrenergic receptor signaling in Chinese hamster ovary cells: l-isoproterenol selectively activates G(s).
    Brink CB; Wade SM; Neubig RR
    J Pharmacol Exp Ther; 2000 Aug; 294(2):539-47. PubMed ID: 10900230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.
    Millan MJ; Dekeyne A; Newman-Tancredi A; Cussac D; Audinot V; Milligan G; Duqueyroix D; Girardon S; Mullot J; Boutin JA; Nicolas JP; Renouard-Try A; Lacoste JM; Cordi A
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1192-205. PubMed ID: 11082457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation in a protein kinase C phosphorylation site of the 5-HT1A receptor preferentially attenuates Ca2+ responses to partial as opposed to higher-efficacy 5-HT1A agonists.
    Wurch T; Colpaert FC; Pauwels PJ
    Neuropharmacology; 2003 Jun; 44(7):873-81. PubMed ID: 12726819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reciprocal modulation of alpha(2A)-adrenoceptor and G(alpha o) protein states as determined by carboxy-terminal mutagenesis of a G(alpha o) protein.
    Wurch T; Okuda J; Pauwels PJ
    Mol Pharmacol; 2001 Oct; 60(4):666-73. PubMed ID: 11562427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
    Millan MJ; Cussac D; Milligan G; Carr C; Audinot V; Gobert A; Lejeune F; Rivet JM; Brocco M; Duqueyroix D; Nicolas JP; Boutin JA; Newman-Tancredi A
    J Pharmacol Exp Ther; 2001 Jun; 297(3):876-87. PubMed ID: 11356907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of human recombinant alpha(2A)-adrenoceptors expressed in Chinese hamster lung cells using intracellular Ca(2+) changes: evidence for cross-talk between recombinant alpha(2A)- and native alpha(1)-adrenoceptors.
    Reynen PH; Martin GR; Eglen RM; MacLennan SJ
    Br J Pharmacol; 2000 Apr; 129(7):1339-46. PubMed ID: 10742289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand recognition of serine-cysteine amino acid exchanges in transmembrane domain 5 of alpha2-adrenergic receptors by UK 14,304.
    Cockcroft V; Frang H; Pihlavisto M; Marjamäki A; Scheinin M
    J Neurochem; 2000 Apr; 74(4):1705-10. PubMed ID: 10737629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.